Skip to main content
Menu
US

AlphaLISA SureFire Ultra Human and Mouse Cleaved PARP1 D214 Detection Kit, 50,000 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Cleaved PARP1 D214 assay is a sandwich immunoassay for quantitative detection of cleaved PARP1 D214 in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Protein Quantification

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Cleaved PARP1 D214 assay is a sandwich immunoassay for quantitative detection of cleaved PARP1 D214 in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 100 Assay Points
Part #:
ALSU-CPARP1-A-HV
List Price
USD 694.00
Unit Size: 500 Assay Points
Part #:
ALSU-CPARP1-A500
List Price
USD 2,346.00
Unit Size: 10,000 Assay Points
Part #:
ALSU-CPARP1-A10K
List Price
USD 14,270.00
Unit Size: 50,000 Assay Points
Part #:
ALSU-CPARP1-A50K
List Price
USD 46,060.00

Overview

Cleaved Poly (ADP-ribose) polymerase 1 (PARP1) is a marker of apoptosis, a form of programmed cell death. PARP1 is a DNA repair enzyme that becomes activated in response to DNA damage. During apoptosis, PARP1 is cleaved by caspases, specifically at Asp214, rendering it inactive and preventing DNA repair, which facilitates the apoptotic process. Cleaved PARP1 serves as an important biomarker for apoptosis in cancer research and therapeutic assessment.

The AlphaLISA SureFire Ultra Human and Mouse Cleaved PARP1 D214 Detection Kit is a sandwich immunoassay for the quantitative detection of Cleaved PARP1 D214 in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

 

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

 

Alpha SureFire Ultra kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • Screening

 

Specifications

Application
Protein Quantification
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Host Species
Human
Mouse
Molecular Modification
Total
Product Group
Kit
Shipping Conditions
Shipped in Blue Ice
Target
PARP1 D214
Target Class
Phosphoproteins
Target Species
Human
Technology
Alpha
Therapeutic Area
Oncology
Unit Size
50,000 Assay Points

How it works

Total-AlphaLISA SureFire Ultra assay principle

The Total-AlphaLISA SureFire Ultra assay measures the expression level of a protein target in a cell lysate.

The Total-AlphaLISA SureFire Ultra assay uses two antibodies which recognize two different distal epitopes on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure™ tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of targeted protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.

Assay Principle Total AlphaLISA SureFire Ultra

 

Total-AlphaLISA SureFire Ultra two-plate assay protocol

The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells' viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.

2plates-assay-protocol-AlphaLISA-Surefire-Ultra.jpg
Total-AlphaLISA SureFire Ultra one-plate assay protocol

Detection of Total target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.

1 plate assay protocol AlphaLISA Surefire Ultra

Assay validation

Activation of cleaved PARP1 (Asp214) in Staurosporine treated human cells

HeLa cells were seeded in a 96-well plate (40,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of Staurosporine for 4 hours in serum free medium.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Cleaved PARP1 (Asp214) and Total Cofilin were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells or 800 cells for Total Cofilin) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, Staurosporine triggered a dose-dependent increase in the levels of Cleaved PARP1 (Asp214) while Total Cofilin levels remained unchanged.

Pharmacological Validation (activator) of Cleaved PARP1 (Asp214)
Activation of cleaved PARP1 (Asp214) in Staurosporine treated mouse cells

RAW 264.7 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of Staurosporine for 4 hours in serum free medium.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Cleaved PARP1 (Asp214) and Total ERK1/2 were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, Staurosporine triggered a dose-dependent increase in the levels of Cleaved PARP1 (Asp214) while Total ERK1/2 levels remained unchanged.

Pharmacological Validation (activator) of Cleaved PARP1 (Asp214)
Inhibition of cleaved PARP1 (Asp214) in Olaparib treated cells

HeLa cells were seeded in a 96-well plate (40,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were pretreated with 1 µM Staurosporine for 4 hours in serum free medium, followed by treatment with increasing concentrations of Olaparib for 10 minutes.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Cleaved PARP1 (Asp214) and Total Cofilin were evaluated using respective AlphaLISA SureFire Ultra assays.

Pharmacological Validation (inhibitor) of Cleaved PARP1 (Asp214)

For the detection step, 10 µL of cell lysate (approximately 4,000 cells or 800 cells for Total Cofilin) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, Olaparib, a well validated PARP1/2 inhibitor, triggered a dose-dependent inhibition of Cleaved PARP1 (Asp214) while Total Cofilin levels remain unchanged.

Assay specificity/selectivity

Specificity of cleaved PARP1 (Asp214) assay

Cleaved PARP1 (Asp214) protein levels were assessed in A549 wild type (WT) and A549 PARP1 knockout (KO) (Abcam, ab276094) cells. Both cell lines were grown to confluency in a T75 flask in medium at 37°C, 5% CO2. Each flask was treated with 1 µM Staurosporine for 4 hours in serum free medium and then lysed in 2 mL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Lysates were then serially diluted in Lysis Buffer and evaluated for Cleaved PARP1 (Asp214) using the AlphaLISA SureFire Ultra kit.

Specificity of Cleaved PARP1 (Asp214) assay

For the detection step, 10 µL of cell lysate was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, Cleaved PARP1 (Asp214) was only detected in the WT A549 cells but not in the A549 PARP1 KO cell line, demonstrating assay specificity. Assay background is represented with a dotted line.

Resources

Are you looking for resources, click on the resource type to explore further.

Scroll Icon